Completed PHASE2 INTERVENTIONAL 2-arm NCT01813136

Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma

A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma

Sponsor: Centre Leon Berard

Conditions Thyroid Carcinoma

Interventions Continuous pazopanib (Arm A) Intermittent pazopanib (Arm B)

Updated 6 times since 2017 Last updated: Aug 14, 2019 Started: Mar 31, 2013 Primary completion: Jan 31, 2019 Completion: Jan 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01813136, this PHASE2 trial focuses on Thyroid Carcinoma and remains completed. Sponsored by Centre Leon Berard, it has been updated 6 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Sep 2019 — Jan 2021 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Jun 2018 — Sep 2019 [monthly]

Recruiting PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

Mar 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centre Leon Berard
GlaxoSmithKline

Data source: Centre Leon Berard

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Angers, France , Bordeaux, France , Caen, France , Lille, France , Lyon, France , Marseille, France , Nice, France , Paris, France , Reims, France , Toulouse, France and 1 more location